Key facts
- Phagenesis’s last known valuation is $51.3M (Aug 2025).
- It has raised $90.0M.
- Notable investors include MedTech Innovator, British Business Bank, Wellcome Trust, Northern Gritstone, Nestlé Health Science — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Phagenesis
- ·The full record, as it builds
Funding rounds
No funding rounds for Phagenesis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phagenesis
Developer of a medical device designed to provide treatment of acute dysphagia. The company's device helps harness the brain's capacity for relearning functions that have been lost through brain damage via neuroplasticity or cortical remapping through neurostimulation therapy and offers a non-surgical, personalized treatment using pharyngeal electrical stimulation (PES), enabling patients to restore the neurological control of swallowing and accelerate recovery.
- Sector
- Healthcare
- HQ
- Manchester, United Kingdom
- Founded
- 2007
- Employees
- 65
- Website
- phagenesis.com/
- Ownership
- Privately Held (backing)
Phagenesis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phagenesis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phagenesis in its N-PORT filings yet. We sweep new filings monthly.